Skip to content

Study · Systematic review · 2015

1 result

Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.

Su B, Sheng H, Zhang M, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S, Wang J

Endocrine30 Jul 2014Cited by 158 (Europe PMC)

PMID25074632 (opens in a new tab)DOI10.1007/s12020-014-0361-4 (opens in a new tab)PepBankPUB-25074632
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials, liraglutide treatment was associated with a significantly lower risk of incident bone fractures than comparators.

    In plain wordsIn a pooled analysis of trials, liraglutide was linked to fewer bone fractures than placebo or other drugs.

    Peptide
    Liraglutide
    Outcome
    DecreaseIncident bone fractures
    Study

    n: not reported in source

    Comparator
    Placebo or other active drugs
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    MH-OR
    0.38 ratio
    incident bone fractures

    Source sentences

    Summary
    Liraglutide treatment was associated with a significant reduced risk of incident bone fractures (MH-OR=0.38, 95% CI 0.17-0.87)
    1 context sentence
    Summary · context
    We performed a meta-analysis including randomized controlled trials (RCT) to study the risk of bone fractures associated with liraglutide or exenatide, compared to placebo or other active drugs.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02473809

The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

University of Aarhusn = 60Aug 2015 to Oct 2017

Diabetes Complications · Osteoporosis

Trial pageClinicalTrials.govUpdated 26 Sept 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.